

# Jeffrey P Ward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7040852/publications.pdf>

Version: 2024-02-01

27  
papers

4,558  
citations

430754

18  
h-index

526166

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

10343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	0.6	17
2	Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 856132.	1.3	2
3	BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. <i>Cancer Immunology Research</i> , 2022, 10, 597-611.	1.6	16
4	Cause of death among patients with non-small cell lung cancer treated with postoperative radiation therapy (PORT).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20555-e20555.	0.8	1
5	<i>Bcl6</i>-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection. <i>Journal of Immunology</i> , 2021, 207, 125-132.	0.4	4
6	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	62
7	Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. <i>Journal of Clinical Oncology</i> , 2021, 39, 3747-3758.	0.8	38
8	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , 2020, 183, 818-834.e13.	13.5	287
9	cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. <i>Nature</i> , 2020, 584, 624-629.	13.7	298
10	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	3.2	28
11	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , 2019, 574, 696-701.	13.7	563
12	Role of immune checkpoint blockers in patients with EGFR mutation. <i>Translational Lung Cancer Research</i> , 2018, 7, S385-S387.	1.3	2
13	High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. <i>Cell</i> , 2018, 175, 1014-1030.e19.	13.5	292
14	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	1.6	236
15	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. <i>Cancer Immunology Research</i> , 2016, 4, 1007-1015.	1.6	84
16	143â€ŒIdentification of Neoantigen-specific CD8+ T Cells in Two Murine Orthotopic Glioblastoma Models Using Cancer Immunogenomics. <i>Neurosurgery</i> , 2016, 63, 158.	0.6	2
17	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
18	Understanding the molecular manipulation of DCAF1 by the lentiviral accessory proteins Vpr and Vpx. <i>Virology</i> , 2015, 476, 19-25.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	13.7	1,705
20	Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	11
21	Degranulation of Natural Killer Cells Following Interaction with HIV-1-Infected Cells Is Hindered by Downmodulation of NTB-A by Vpu. <i>Cell Host and Microbe</i> , 2010, 8, 397-409.	5.1	172
22	HIV-1 Vpr Triggers Natural Killer Cell-Mediated Lysis of Infected Cells through Activation of the ATR-Mediated DNA Damage Response. <i>PLoS Pathogens</i> , 2009, 5, e1000613.	2.1	110
23	Role of natural killer cells in HIV pathogenesis. <i>Current HIV/AIDS Reports</i> , 2008, 5, 44-50.	1.1	12
24	Lysis of Endogenously Infected CD4+ T Cell Blasts by rIL-2 Activated Autologous Natural Killer Cells from HIV-Infected Viremic Individuals. <i>PLoS Pathogens</i> , 2008, 4, e1000101.	2.1	88
25	HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. <i>Blood</i> , 2007, 110, 1207-1214.	0.6	158
26	Regulation of CD4 Expression via Recycling by HRES-1/RAB4 Controls Susceptibility to HIV Infection. <i>Journal of Biological Chemistry</i> , 2006, 281, 34574-34591.	1.6	58
27	HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. <i>Aids</i> , 2004, 18, 1769-1779.	1.0	57